A huge shoutout to our amazing KU Heme Pharmacists! 🎉 They’ve put in so much effort this year, and we want to celebrate everything they’ve achieved with our #USMIRC group! Big thanks for their hard work! Thanks a ton to Jordan Snyder, Sara Leidy, PharmD, BCOP, Michael Weise, PharmD, BCOP, and

On Wednesdays, the hematology consult team wears pink. Lots of compliments on the rounds today! Abdulraheem Yacoub

🚨 Sending some lunch money to some trainees 🚨 Are there 100 residents/fellows on this app who are working tonight? Because our family would like to send you $20 for a meal to share our gratitude for how hard y’all are working, for the benefit of your communities! DMs open!

#myeloMATCH MM1YA-S01 is enrolling adults ages 18-59 with newly diagnosed high-risk #AML. Randomized 5-arm comparison of induction therapies. Primary endpoint: MRD-negative complete remission rate. SWOG.org/clinical-trial… Co-PI: Tara Lin, MD KU Cancer Center #leusm #AMLsm

Just some of the posters from the KU Cancer Center team at #Tandem25 🤩 Well done team!! 🌺🌅 Jordan Snyder Al-Ola A Abdallah MD (USMIRC)

Done from the Malignant Hematology Panel Binaytara with speakers KU Cancer Center Nausheen Ahmed MD Abdulraheem Yacoub Dr. Marc Hoffmann Dr Aung Tun #MedEd #MedTwitter OncoAlert USMIRC News

Check out are latest episode, with a star-studded cast! 🤩 "Dex and the Cytokine City: Managing CRS with Bispecifics" #leusm #lymsm #myeloma #TwitteRx @berninini James Davis, PharmD, BCOP Victoria Nachar Anthony Perissinotti Justine Preedit creators.spotify.com/pod/show/wolve…

Great to participate in #HOPA25 this year for a panel with some great pharmacists: Emilie Aschenbrenner and Joe Kalis discussing lymphoma bispecifics, CRS management, out-patient administration, and more. #Lymsm #Lymphoma PTCE

Nice review on FL Rituximab Eva Kimby. The role of maintenance R is debatable. Patient preferences are always key, no OS benefit, PFS/TTNT benefit, retreatment is often an option for prolonged responders. #Lymsm thelancet.com/journals/lanha…

Great lecture from Jordan Snyder to our heme/onc fellows on CRS/ICANs management of both solid tumor and heme bispecific antibodies. Important topic for all to be familiar with. #Lymsm #Lymphoma #Bispecifics #MedTwitter KU Cancer Center KU Heme Onc Fellowship

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results | Journal of Clinical Oncology #Lymsm ascopubs.org/doi/10.1200/JC…

MCL: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches | Journal of Clinical Oncology. Front line BTK is here and will stay. #lmsm #MedTwitter ascopubs.org/doi/abs/10.120…

This is an interesting concept and T cell exhaustion is an important focus for treatment failures. Multi-virus specific T cells to enhance the activity of bispecific antibodies in lymphoma by ⁦Akiva Diamond⁩ #Lymsm #lymphoma #ASCO25 ascopubs.org/doi/10.1200/JC…

Excited to dive into this one for some casual reading. It’s a small book so should be quick read. I’ll post my thoughts once finished :) #MedTwitter #Hematology

Goodbye fellow cubicle, we anxiously await the attending office. Many hours spent here: charting, editing papers, studying, spinning the proverbial hamster wheel. Ready for the next phase of my career!

Prophy dex with glofitamab (4 mg after 1st glofi & bid for 3 days after C1D8, C1D15, C2D1) with reduction in CRS from 63% in trial to 32%, all G1-2. Moving towards outpatient glofi. #18ICML #lymsm

Structured Exercise after Adjuvant Chemo for Colon Cancer ⁦KU Heme Onc Fellowship⁩ with Dr. Sunny Cai and Dr. ⁦Li Haoran, MD, PhD⁩ . Good for all cancer patients to exercise post-chemo, but especially CRC! 🏃🏊 #MedTwitter #ColonCancer #ExerciseIsmedicine nejm.org/doi/full/10.10…

We’re in Briarcliff! Now patients have 3 locations to choose from in the Northland. Ranked in the top 1% nationwide, #KUCancerCenter offers unrivaled expertise and experience in diagnosing and treating all forms of cancer. Learn more: bit.ly/3ZGWiQI

Zanubrutinib demonstrated reduced risk of progression/death compared to ibrutinib, acalabrutinib, and bendamustine or idelalisib+rituximab. ow.ly/HtOG50WfGUG #lymphoidneoplasia

⏳2 days left for the 1st National ICE-T meeting #mmsm #USMIRC OncoAlert OncoDaily Nausheen Ahmed MD Jose Sandoval S, MD FACP 🇨🇴🇨🇴 Moazzam Shahzad, MD Muhammad Umair Mushtaq (Abu Mikael) Zahra M, PharmD, MBA, BCOP, FHOPA Anup Kasi MD MPH Shebli Atrash @medicalwatchBC LARVOL eeds.com/portal_live_ev…